Chai Xiangting, Liu Qiaoyu, Shao Wenyu, Zhang Feng, Wang Xuehao, Wang Hai
Department of Internal Medicine, Jiaonan People's Hospital of Shandong Province, Jiaonan, Shandong 266400, China;
J Biomed Res. 2012 May;26(3):165-9. doi: 10.7555/JBR.26.20110075. Epub 2012 Apr 12.
(99m)Tc-methoxyisobutyl isonitrile (MIBI) is a suitable transport substrate for the multidrug resistance gene product P-glycoprotein (P-gp) and widely used for tumor imaging. Bromocriptine has been shown to inhibit the ATPase activity and the function of P-gp. We hypothesized that bromocriptine could promote the accumulation of MIBI by inhibiting P-gp activities, a feature that can be taken advantage of for enhancing (99m)Tc-MIBI imaging. In the current study, we sought to investigate whether bromocriptine enhanced the uptake of (99m)Tc-MIBI in hepatocellular carcinoma patients. Sixty primary hepatocellular carcinoma patients received (99m)Tc-MIBI single photon emission computer tomgraphy (SPECT) prior to surgery. (99m)Tc-MIBI SPECT was performed 15 and 120 min after injection of 20 mCi (99m)Tc-MIBI, and early uptake, delayed uptake (L/Nd), and washout rate (L/Nwr) of (99m)Tc-MIBI were obtained. In addition, a second (99m)Tc-MIBI SPECT was performed according to the same method 48 h after bromocriptine administration. We found that, prior to bromocriptine administration, significant MIBI uptake in tumor lesions was noted in only 10 (16.7%, 10/60) patients with hepatocellular carcinoma. No significant MIBI uptake was observed in the tumor lesions of the remaining 50 (83.3%, 50/60) hepatocellular carcinoma patients. Following bromocriptine administration, all the patients without apparent MIBI uptake demonstrated significant MIBI uptake on (99m)Tc-MIBI SPECT (P < 0.05). Our findings indicate that bromocriptine enhances the uptake of (99m)Tc-MIBI in patients with hepatocellular carcinoma.
锝-99m甲氧基异丁基异腈（MIBI）是多药耐药基因产物P-糖蛋白（P-gp）合适的转运底物，广泛用于肿瘤显像。已证实溴隐亭可抑制P-gp的ATP酶活性及其功能。我们推测溴隐亭可通过抑制P-gp活性促进MIBI的蓄积，这一特性可用于增强锝-99m MIBI显像。在本研究中，我们试图探讨溴隐亭是否能增强肝细胞癌患者对锝-99m MIBI的摄取。60例原发性肝细胞癌患者在手术前行锝-99m MIBI单光子发射计算机断层扫描（SPECT）。静脉注射20 mCi锝-99m MIBI后15分钟和120分钟行锝-99m MIBI SPECT检查，获得锝-99m MIBI的早期摄取、延迟摄取（L/Nd）和洗脱率（L/Nwr）。此外，在给予溴隐亭48小时后，按照相同方法再次行锝-99m MIBI SPECT检查。我们发现，在给予溴隐亭之前，仅10例（16.7%，10/60）肝细胞癌患者的肿瘤病灶有明显的MIBI摄取。其余50例（83.3%，50/60）肝细胞癌患者的肿瘤病灶未观察到明显的MIBI摄取。给予溴隐亭后，所有未出现明显MIBI摄取的患者在锝-99m MIBI SPECT上均显示出明显的MIBI摄取（P<0.05）。我们的研究结果表明，溴隐亭可增强肝细胞癌患者对锝-99m MIBI的摄取。
